Approval of Inavolisib: A Leap Forward in Precision Breast Cancer Therapy With Jason Mouabbi, MD
Expert Perspectives · Keira Smith · 2024-10-14
The FDA has granted approval to inavolisib in combination with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer. Just hours after the approval, OncData Editorial Board member Dr. Jason Mouabbi, Assistant Professor in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center, sat down with us to share more about this exciting approval and the significant step forward that it represents in the field of personalized medicine for breast cancer. Dr. Mouabbi sheds light on:
- The need for tailored therapies for this population and why inavolisib was investigated
- The results of the INAVO120 trial that investigated the combination
- What the approval means for patients with this subset of breast cancer and how it impacts treatment options
- Considerations for mutation testing
- What patients and providers should know about side effects and how to manage them
- Big-picture perspectives on how inavolisib fits into the field of personalized medicine for breast cancer
- And more!
“It’s a very exciting time as we’re seeing precision oncology coming to the earlier line. This is definitely a strong and solid step in the right direction for a better future for our patients with this type of disease. This is a big leap in breast cancer, and I’m looking forward to seeing more agents make it to the early setting.” – Jason Mouabbi, MD
About Dr. Mouabbi
Jason Mouabbi, MD, is an Assistant Professor in the Department of General Oncology and the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center, where he specializes in lobular breast cancers. His research focuses on the management of breast cancer subtypes and their impact on treatment. Dr. Mouabbi has been the recipient of multiple honors and awards, including the Guiding Researchers and Advocates to Scientific Partnerships (GRASP) Advocate Choice Award in 2022 and the Lester & Sue Smith Breast Cancer Award of Excellence in 2021.